Advertisement

Topics

AZ immunotherapy gets FDA boost in early lung cancer

08:30 EDT 31 Jul 2017 | pharmaphorum

The FDA may have offered struggling AstraZeneca a lifeline, granting a “breakthrough” designation for its cancer immunotherapy Imfinzi in early-stage lung cancer. AZ is reeling from poor results from the MYSTIC trial, which last week showed a ...

Original Article: AZ immunotherapy gets FDA boost in early lung cancer

NEXT ARTICLE

More From BioPortfolio on "AZ immunotherapy gets FDA boost in early lung cancer"

Quick Search
Advertisement
 

Relevant Topics

The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...

Cancer
  Bladder Cancer Brain Cancer Breast Cancer Cancer Cervical Cancer Colorectal Head & Neck Cancers Hodgkin Lymphoma Leukemia Lung Cancer Melanoma Myeloma Ovarian Cancer Pancreatic Cancer ...